IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I have certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therefore being fitted with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Applicant: Linda A. Sherman

Serial No.: 09/277,064

Filed: March 26, 1999

Title: IN VIVO ACTIVATION OF TUMOR-

SPECIFIC CYTOTOXIC T CELLS

RECEIVED Group Art Unit: 1642

Examiner: M. Davis

NOV 1 62000

TECH CENTER 1600/2900

Our Ref.: TSRI 443.1D1

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Assistant Commissioner for Patents Washington, D.C.

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed October 4, 2000, enclosed is a Substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Substitute Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Substitute Sequence Listing is labeled SCR2152S.APP.

Entry of the following amendments and consideration of the Remarks that follow is respectfully requested.

Please amend the above-identified application as follows: